menu
    • menu
    [{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Loratadine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Loratadine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Loratadine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Loratadine

    Menu

    Loratadine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Strides Pharma Science

    India
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

    Lead Product(s) : Loratadine

    Therapeutic Area : Immunology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Strides Receives USFDA Approval for Loratadine OTC Softgel Capsules

    Details : USFDA approved generic version Loratadine Softgel Capsules is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies.

    Product Name : Claritin Liqui-Gels-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 16, 2020

    Lead Product(s) : Loratadine

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Marksans Pharma

    India arrow
    ELCC
    Not Confirmed

    Marksans Pharma

    India arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Loratadine

    Therapeutic Area : Immunology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Marksans Pharma Gains After Receiving Final Nod for Loratadine Tablets from USFDA

    Details : Clartin-Generic (loratadine) is been approved by USFDA. It is indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for OTC.

    Product Name : Clartin-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 22, 2024

    Lead Product(s) : Loratadine

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    J.B.Chemicals & Pharmaceuticals

    India arrow
    ELCC
    Not Confirmed

    J.B.Chemicals & Pharmaceuticals

    India arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Loratadine

    Therapeutic Area : Immunology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    JB Chemicals Gets USFDA Nod for Generic Product

    Details : The USFDA has approved company's abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg for treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 08, 2021

    Lead Product(s) : Loratadine

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth